Vor Biopharma Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, 28.84, 141.7, 483.3 ], "ebit_estimate": [ -158.89, -207.25, -261.06, -170.47, 58.38 ], "ebitda_estimate": [ -162.39, -211.13, -290.81, null, null ], "net_income_estimate": [ -315.16, -198.15, -250.77, -161.62, 8.67 ], "per_share_eps_estimate": [ -6.48, -3.52, -3.71, -2.32, -0.2 ], "eps_nri_estimate": [ -6.5, -3.48, -3.89, -2.32, -0.06 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ -5.59, -26.38, -4.98, null, null ], "pretax_income_estimate": [ -315.16, -198.15, -233.33, -160.14, 12.51 ], "operating_cash_flow_per_share_estimate": [ -2.84, -3.14, -3.32, null, null ], "roa_estimate": [ -77.9, -49.8, -53, null, null ], "roe_estimate": [ 7.7, 10.3, 207.8, null, null ], "gross_margin_estimate": [ null, 79.3, 87, 86.4, 84.7 ], "operating_cash_flow_estimate": [ -122.15, -135.06, -142.8, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": 60.61, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 61.12, "future_eps_nri_estimate_growth": 60.61, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 29.72, "future_pretax_income_estimate_growth": 31.22, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": 38.38, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 35.04 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ null, null, null, null, null, null, null, null ], "ebit_estimate": [ -38.16, -40.81, -44.79, -52.19, -54.95, -56.35, -60.69, null ], "ebitda_estimate": [ -38.74, -41.84, -46.26, null, null, null, null, null ], "net_income_estimate": [ -35.68, -38.21, -42.08, -50.19, -52.95, -54.35, -58.69, null ], "per_share_eps_estimate": [ -0.7, -0.76, -0.84, -0.93, -0.97, -0.97, -1.04, null ], "eps_nri_estimate": [ -0.7, -0.76, -0.83, -0.88, -0.92, -0.92, -0.98, -0.83 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -36.46, -28.32, -30.41, -50.19, -52.95, -54.35, -58.69, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": 60.61, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 61.12, "future_eps_nri_estimate_growth": 60.61, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 29.72, "future_pretax_income_estimate_growth": 31.22, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": 38.38, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 35.04 }